TB-500 (Thymosin Beta-4) Phase I and Phase II safety trials of intravenous thymosin beta-4 published in human cohorts (Ruff et al., 2010)
Supplementary Section A provides full LLM prompts, Supplementary Section B provides details of case study analysis, Supplementary Section C provides an algorithmic overview of the human-in-the-loop procedure used to solve case study molecules, Supplementary Section D provides pseudocode for the DeepRetro top-level algorithm, Supplementary Section E provides pseudocode for the detailed LLM invocation algorithm, Supplementary Section F provides details of customization parameters and the open-source release, Supplementary Section G provides details and screenshots of the GUI, Supplementary Section H provides details of LLM API costs and cloud costs, Supplementary Section I provides details about automation bottlenecks, Supplementary Section J provides details about novelty assessment methodology, and Supplementary Section K provides details about scalability index Weaknesses of DeepRetro A notable challenge encountered during the development and application of our iterative LLM-Retrosynthesis pipeline pertains to the rate of chemically unsound or implausible suggestions generated by the LLM calls
Maximize your results: B12 is one piece of the puzzle
A familiar flare returns
This table illustrates the trade-off perfectly
It has also been associated with upregulation of growth-hormone receptors in tendon fibroblasts, a finding that may help explain reported effects on tendon and ligament tissue
